China SXT Pharmaceuticals, Inc. (SXTC) Stock Price & Analysis
China SXT Pharmaceuticals, Inc. (SXTC) closed at USD 0.04 on Friday, October 23, 2026, down 14.58% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 0.05; the Oct 23, 2026 session ranged USD 0.04–0.05 on volume of 20,319,427 shares. Market capitalization is $4,246, with a 52-week range of USD 0.04–83,760 (NCM). Source: Nexqual, retrieved October 24, 2026 at 12:39 UTC.
Also available as compact Markdown for AI agents: nexqual.com/SXTC.md
Key facts (SXTC)
- Analysts: None.
- Total return with dividends: 1Y -100.0% vs S&P 500 +13.4%; 5Y -100.0% vs S&P 500 +76.9%.
Analysts (SXTC)
Consensus None.
Total return (dividends reinvested) (SXTC)
| 1Y (from 2025-10-24) | 5Y (from 2021-10-25) | |
|---|---|---|
| Total return | -100.0% | -100.0% |
| S&P 500 (SPY) | +13.4% | +76.9% |
| Per year | -100.0% | -95.7% |
| Volatility (annualized) | 454.2% | 307.8% |
| Max drawdown | -100.0% (Jan 2026→Oct 2026) | -100.0% (Jun 2022→Oct 2026) |
SXTC suppliers, customers and competitors (named in its 20-F)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Customer | Jiuzhoutong Pharmaceutical | “to hospitals and other healthcare distributors such as Jiuzhoutong Pharmaceutical Co. Ltd. As of March 31, 2026, our end-customer base” |
Quoted from the company's 20-F filed Jul 1, 2026.
SXTC analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter | — | — | — | $0 | — |
| Next quarter | — | — | — | $0 | — |
| Current fiscal year | — | — | — | $0 | — |
| Next fiscal year | — | — | — | $0 | — |
Key Statistics (as of October 24, 2026 at 12:39 UTC)
| Price | USD 0.04 |
|---|---|
| Change | ▼ 14.58% (down) |
| Previous Close | USD 0.05 |
| Open | USD 0.04 |
| Day Range | USD 0.04 – 0.05 |
| 52-Week Range | USD 0.04 – 83,760 |
| Volume | 20,319,427 shares |
| Market Cap | $4,246 |
| Exchange | NCM |
Technical Analysis (SXTC)
Nexqual's technical model rates SXTC "SELL" based on 1 bullish and 5 bearish signals across 127 daily candles, as of October 24, 2026 at 12:39 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 34 (neutral) |
| vs SMA50 | Below (USD 2.18) |
| MACD | -1.85 (negative) |
Analyst Ratings (SXTC)
Wall Street analysts rate SXTC "None", per Nexqual as of October 24, 2026 at 12:39 UTC.
| Consensus Rating | None |
|---|
Earnings (SXTC)
Source: Nexqual, October 24, 2026 at 12:39 UTC.
Financials & Fundamentals (SXTC)
| Total Revenue | $1.14M |
|---|---|
| Revenue Growth (latest quarter, YoY) | -43.90% |
| Gross Margin | +21.85% |
| Operating Margin | -153.28% |
| Profit Margin | +0.00% |
| ROE | -27.49% |
| Debt / Equity | 0.04 |
| Current Ratio | 7.94 |
| Total Cash | $28.32M |
| Total Debt | $1.12M |
Source: Nexqual, October 24, 2026 at 12:39 UTC.
Financial Health Score (SXTC)
Nexqual rates China SXT Pharmaceuticals, Inc.'s overall financial health "Weak" across five dimensions, as of October 24, 2026 at 12:39 UTC.
| Growth | Critical — Revenue -44% YoY (latest Q), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $28M cash vs $1M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$4M (TTM) |
| Efficiency | Critical — ROE -27%, ROA -15.8% |
Ownership (SXTC)
| Insider Ownership | +15.00% |
|---|---|
| Institutional Ownership | +0.00% |
| Shares Outstanding | 103,574 |
| Float | 401,683 |
| Short % of Float | +4.96% |
Source: Nexqual, October 24, 2026 at 12:39 UTC.
Leadership (SXTC)
China SXT Pharmaceuticals, Inc. is led by Feng Zhou, Chairman of the Board & Co-CEO, per Nexqual as of October 24, 2026 at 12:39 UTC.
| Chairman of the Board & Co-CEO | Feng Zhou |
|---|---|
| Chief Financial Officer | Xiaodong Pan |
| Executive Director | Jun Zheng |
Major Backers & Investors (SXTC)
Notable institutional backers of China SXT Pharmaceuticals, Inc. include Sabby Management, LLC, according to Nexqual as of October 24, 2026 at 12:39 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Sabby Management, LLC | 8.16% |
Source: Nexqual, October 24, 2026 at 12:39 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| SUPN | Supernus Pharmaceuticals, Inc. | USD 40.7 | ▼ 3.26% |
| BHC | Bausch Health Companies Inc. | USD 6.44 | ▼ 0.77% |
| HCM | HUTCHMED (China) Limited | USD 14.36 | ▲ 0.56% |
| AMLX | Amylyx Pharmaceuticals, Inc. | USD 27.2 | ▼ 4.8% |
| RGC | Regencell Bioscience Holdings L | USD 7.67 | ▼ 21.81% |
| LQDA | Liquidia Corporation | USD 42.65 | ▲ 7.46% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 24, 2026 at 12:39 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt